1144.5000 1.90 (0.17%)
NSE May 19, 2025 15:31 PM
Volume: 139.1K
 

1144.50
0.17%
AUM Capital
Glenmark Life Sciences (GLS) is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. It also manufactures and sells Active Pharmaceutical Ingridients (APIs) for gastro-intestinal disorders, antiinfectives and other therapeutic areas. As of March 2021, GLS had a portfolio of 120 molecules globally and sold APIs in India and exported APIs to multiple countries in Europe, North America, Latin America,...
Number of FII/FPI investors increased from 92 to 105 in Mar 2025 qtr.
More from Alivus Life Sciences Ltd.
Recommended